Despite its promising in vitro efficacy, PF-06873600’s clinical development was discontinued due to significant toxicity, underscoring the challenges in simultaneously targeting multiple Cyclin-dependent kinases (CDK2/4/6) to treat human cancers. The gene discussed is CDK2; the disease is cancer.